Research of 10-23 DNAZyme inhibit the expression of eIF4E genes.
- Author:
Bo TENG
1
;
Ding XIN
;
Lianji WEN
;
Shuxun CUI
;
Chunshun JIN
Author Information
1. Department of Otolaryngology, Second Hospital of Jilin University,Changchun 130041, China. tengbo1975@163.com
- Publication Type:Journal Article
- MeSH:
Apoptosis;
Cell Line, Tumor;
DNA, Catalytic;
genetics;
DNA, Single-Stranded;
genetics;
Eukaryotic Initiation Factor-4E;
genetics;
metabolism;
Gene Expression;
Genetic Therapy;
Humans;
Laryngeal Neoplasms;
genetics;
RNA, Messenger;
genetics;
Transfection
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2007;21(12):552-554
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the possibility of 10-23DNAzyme becoming a new gene therapy for laryngeal carcinoma treatment at the cell level.
METHOD:Thiosthorothioate 10-23DNAzyme specific to eIF4E gene mRNA 1059 was designed and synthesized, and its inhibition effects on the expression of eIF4E gene in Hep-2 cells were observed.
RESULT:The expression of eIF4E gene was remarkable depressed after Hep-2 cells was transfected by DNAzyme. The level of inhibiting eIF4E in hep-2 cells transfected by DNAzyme was lower than that by only lipofectamine 2000 transfected and Hep-2.
CONCLUSION:The expression of eIF4E gene in Hep-2 cells 10-23DNAzyme can be highly blocked. It is a specific and effective gene therapeutic means.
